Navigation Links
CuraGen Reports Second Quarter 2009 Financial Results
Date:7/31/2009

linical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB. "We continue to be very positive about the development opportunities for CR011 in breast cancer and melanoma," commented Dr. Timothy M. Shannon, President and Chief Executive Officer of CuraGen. "We look forward to presenting updated data for the breast cancer study in the second half of 2009."

In July 2009, CuraGen also reached an agreement in principle and signed a memorandum of understanding to settle two shareholder class action lawsuits that had been filed in connection with the proposed merger between CuraGen Corporation and Celldex Therapeutics, Inc. The settlement is subject to documentation and court approval. "While we continue to deny any wrongdoing or liability with respect to the claims asserted in the class action suits, unfortunately, the monthly costs of defending against these lawsuits far outweighed the benefits of continued litigation. Therefore, we have agreed to the terms of a settlement, which will include additional disclosure in the final proxy statement regarding the merger and, if approved by the court, a payment for the shareholder plaintiffs' attorneys' fees and expenses. Although we expect to have some increases to our initial projections of net cash at closing from the repurchase of debt at a discount as partial offsets, we now expect that the settlement payment and the monthly defense costs in connection with these class action suits will result in a decrease in the net cash at closing from our original projection of $54.5 million to between $53.5 and $54.0 million," commented Dr. Shannon.

The revised projected net cash figures results in a reduction of the expected purchase price for CuraGen from $94.5 million or $1.56 per fully diluted share, to between $93.5 million and $94.0 million or $1.54 - $1.55 per fully diluted share. The proposed merger is projected to close in the third quarter of 2009.

'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
2. CuraGen Reports Third Quarter 2008 Financial Results
3. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
4. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
5. CuraGen to Present at the BIO CEO & Investor Conference
6. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
7. CuraGen Corporation Receives Notification from NASDAQ
8. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
9. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
10. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
11. CuraGen Appoints Clinical Oncologist as VP of Medical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/27/2015)... ... 27, 2015 , ... Proove Biosciences, a commercial and ... of genetics and hypertension at the International Academy of Cardiology Annual ... Canada. The event, which boasts an extensive overview of the latest research developments ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... CHAPEL HILL, N.C., Nov. 5 As ... market, considerable efforts,are placed on strategy and ... largely focus on revenue growth and little ... launch excellence, a recent study,was conducted by ...
... Assay Designs, Inc., a leading,provider of ... life science,and translational research markets, has announced ... The agreement enables Assay Designs to,distribute approximately ... their U.S. and Canadian customers. This major ...
... N.Y., Nov. 5 Misonix, Inc.,(Nasdaq: MSON ... device,technology, which in Europe is used for the ... conditions, has entered into a new, three,year, exclusive ... Rotterdam, The Netherlands, for the distribution of the,SonaStar(TM) ...
Cached Biology Technology:New Study Provides Key Findings for Biopharma Product Launch Evaluation 2Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan 2Misonix Announces New Distribution Agreement for The Netherlands 2Misonix Announces New Distribution Agreement for The Netherlands 3
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... at the University of California, Riverside has received an education fellowship ... encourage more Hispanic students to take an interest in and perform ... professor in the Department of Botany and Plant Sciences ... has been selected to participate in the 2011 USDA E. ...
... BOSTON (April 29, 2011) A gene therapy approach ... in slowing the signs of age-related macular degeneration (AMD), ... at Tufts University School of Medicine. Led by senior ... first time that CD59 delivered by a gene therapy ...
... , , , , , ... , , ... Several fish can be heard in... , Click here for more information. ... , , , , , , ...
Cached Biology News:Fellowship to UC Riverside botanist encourages Hispanic students to take up research 2Fellowship to UC Riverside botanist encourages Hispanic students to take up research 3Gene therapy shows promise against age-related macular degeneration 2Jump in communication skills led to species explosion in electric fishes 2Jump in communication skills led to species explosion in electric fishes 3Jump in communication skills led to species explosion in electric fishes 4Jump in communication skills led to species explosion in electric fishes 5Jump in communication skills led to species explosion in electric fishes 6Jump in communication skills led to species explosion in electric fishes 7
... is a bovine protein-free alternative to ... an aqueous solution that contains non-toxic ... (3-(N-Morpholino) propanesulfonic acid), pH 6.0 - ... 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
... software with the DeCypher Engine accelerator cards to ... perform searches like these from your desktop: ... under 6 days Align BAC-sized queries ... HMM analysis to compare 100,000 sequences to PFAM ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: